The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy
Abstract
Purpose: No effective salvage treatments are available for patients with advanced/recurrent thymoma (T) or thymic carcinoma (TC) who have progressed after platinum-based chemotherapy. This study evaluated the activity of everolimus in patients with advanced/recurrent T or TC previously treated with cisplatin-containing chemotherapy. Patients and Methods: This was a single-arm, single-stage, open-label, multicenter, phase II trial. Patients received oral everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal. A Fleming phase II trial was designed. The null hypothesis of a true disease control rate (DCR) of 40% was tested against a one-sided alternative of a true DCR of 60% (α = β = 0.10): If disease control were achieved in ≥ 21 of the first 41 evaluable patients, everolimus could be recommended for further evaluation. Progression-free survival, overall survival, and safety were also evaluated. Results: From 2011 to 2013, 51 patients were enrolled (T, n = 32; TC, n = 19). Complete remission was observed in one patient with TC, partial response in five patients (T, n = 3; TC, n = 2), and stable disease in 38 patients (T, n = 27; TC, n= 11), with a DCR of 88% (T,: 93.8%; TC, 77.8%). With a median follow up of 25.7 months, median progression-free survival was 10.1 months (T,: 16.6 months; TC, 5.6 months), and median overall survival was 25.7 months (T, not reached; TC, 14.7 months). Fourteen patients had a serious drug-related adverse event; of these patients, nine permanently discontinued treatment. Three patients died of pneumonitis while in the study. Immunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically significantly related to a shorter survival. Conclusion: Everolimus may induce durable disease control in a high percentage of patients with T or TC, albeit with a potential high risk of fatal pneumonitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Cited by
The Integrated Genomic Landscape of Thymic Epithelial Tumors
Radovich, M., Pickering, C. R., Felau, I., Ha, G., Zhang, H., Jo, H., Hoadley, K. A., Anur, P., Zhang, J., McLellan, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.003 · Cited by 381
Cho, J., Kim, H. S., Ku, B. M., Choi, Y.-L., Cristescu, R., Han, J., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.3184 · Cited by 344
Metadata
- Authors
- Zucali, P. A., De Pas, T., Palmieri, G., Favaretto, A., Chella, A., Tiseo, M., Caruso, M., Simonelli, M., Perrino, M., De Vincenzo, F., Toffalorio, F., Damiano, V., Pasello, G., Garbella, E., Ali, M., Conforti, F., Ottaviano, M., Cioffi, A., De Placido, S., Giordano, L., Bertossi, M., Destro, A., Di Tommaso, L., & Santoro, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-02-01
- Volume
- 36
- Issue
- 4
- Pages
- 342-349
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2613990243
- Cited by
- 173
- References
- 2
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. https://app.cochat.ai/papers/10.1200/jco.2017.74.4078
- The paper
- Zucali, P. A., De Pas, T., Palmieri, G., Favaretto, A., Chella, A., Tiseo, M., Caruso, M., Simonelli, M., Perrino, M., De Vincenzo, F., Toffalorio, F., Damiano, V., Pasello, G., Garbella, E., Ali, M., Conforti, F., Ottaviano, M., Cioffi, A., De Placido, S., . . . Santoro, A. (2018). Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.74.4078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.